United States · FDA National Drug Code directory
Deferasirox
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 69539-021_4b237031-5375-4a5a-8a5d-21527f6fc7da
- Product NDC
- 69539-021
- Form
- TABLET, FOR SUSPENSION
- Composition / generic term
- Deferasirox
- Labeler
- MSN LABORATORIES PRIVATE LIMITED
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20191120
- Source listing expiry
- 20261231
Source-listed ingredients
- DEFERASIROX — 125 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 10 BLISTER PACK in 1 CARTON (69539-021-06) / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACK (69539-021-11) · 69539-021-06
- 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-30) · 69539-021-30
- 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-90) · 69539-021-90
- 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-99) · 69539-021-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →